Janwillem Naesens Overview
- Company
- Cyteir Therapeut...
- Primary Position
-
Board Member
- Primary Industry
-
Healthcare
- Active Board Seats
-
4
- Med. Deal Size
-
000.0
- Med. Valuation
-
00000
Janwillem Naesens General Information
Biography
Mr. Janwillem Naesens served as Chief Executive Officer and Board Member at Convert Pharmaceuticals. Je served as Board Member at Bioncotech Therapeutics. He serves as Board Member at Octimet, Frontier Medicines and Cyteir Therapeutics. Mr. Naesens also serves as Managing Partner, Oncology & Droia Group at Droia Ventures. He also serves as Board Member at Ambagon Therapeutics. He was a Board Member of Tusk Therapeutics. He is an investor in early-stage oncology drug development companies, and currently serves on the Board of Directors of 6 biotech companies in Europe and the US. Before DROIA, he was Investment Manager at Waterland Private Equity, a European investment group providing growth capital to small and mid-sized companies. He started his career at McKinsey & Company in New York as a strategy consultant in life sciences and financial services and holds an MSc in Engineering from the University of Leuven and an MBA from INSEAD.
Contact Information
Address
- Da Vincilaan 1
- 1930 Zaventem
- Belgium
Janwillem Naesens Positions (1)
| Firm name | Firm type | Title | Location | Industry | Since |
|---|---|---|---|---|---|
| Droia Ventures | Investor | Managing Partner, Oncology & Droia Group | Zaventem, Belgium | Venture Capital |
Janwillem Naesens Board Seats (4)
| Company | Industry | Ownership Status | Financing Status | Location | Since |
|---|---|---|---|---|---|
| Ambagon Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | San Francisco, CA | |
| Frontier Medicines | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | San Francisco, CA | 0000-00-0 |
| Highlight Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Valencia, Spain | 0000-00-0 |
| Octimet Oncology | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Ghent, Belgium | 0000-00-0 |
Janwillem Naesens Lead Partner on Deals (8)
| Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
|---|---|---|---|---|---|---|
| Frontier Medicines | 26-Feb-2024 | Later Stage VC (Series C) | 00000 | Completed | Drug Discovery | San Francisco, CA |
| Ambagon Therapeutics | 05-Jan-2022 | 00000 00000 00 | 0000 | Completed | Drug Discovery | San Francisco, CA |
| Frontier Medicines | 25-Jun-2021 | 00000 00000 00 | 000.00 | Completed | Drug Discovery | San Francisco, CA |
| Cyteir Therapeutics | 11-Feb-2021 | 00000 00000 00 | 0000 | Completed | Drug Discovery | Lexington, MA |
| Frontier Medicines | 25-Jun-2019 | 00000 00000 00 | 0000 | Completed | Drug Discovery | San Francisco, CA |
| Convert Pharmaceuticals | 28-Feb-2018 | 00000 00000 00 | 000.00 | Completed | Drug Discovery | Liege, Belgium |
| Cristal Therapeutics | 19-Jan-2017 | Later Stage VC | 000.00 | Completed | Drug Discovery | Maastricht, Netherlands |
| Octimet Oncology | 18-Jan-2017 | Early Stage VC (Series A) | 000.00 | Completed | Drug Discovery | Ghent, Belgium |
Janwillem Naesens Network (108)
Board Members (45)
| Name | Company | Representing | Location | From |
|---|---|---|---|---|
| Donald Corcoran | Cyteir Therapeutics | Cyteir Therapeutics | Lexington, MA | |
| Derek DiRocco Ph.D | Frontier Medicines | RA Capital Management | San Francisco, CA | 0000-00-00 |
| 000000000 0 | Octimet Oncology | V-Bio Ventures | Ghent, Belgium | 0000-00-00 |
| 00000 00000 | Cyteir Therapeutics | Cyteir Therapeutics | Lexington, MA | |
| 00000 00000 | Ambagon Therapeutics | MRL Ventures Fund | San Francisco, CA | 0000-00-00 |
Portfolio Executives (57)
| Name | Company | Role | Deal date | Location |
|---|---|---|---|---|
| Gregory Chow | Frontier Medicines | Chief Financial Officer | 26-Feb-2024 | San Francisco, CA |
| Gerardo Ubaghs | Frontier Medicines | Chief Financial Officer | 26-Feb-2024 | San Francisco, CA |
| 0000 0ä00 | Frontier Medicines | Advisor | 26-Feb-2024 | San Francisco, CA |
| 00000 000 | Frontier Medicines | Co-Founder, Chief Executive Officer, President & Chairman | 26-Feb-2024 | San Francisco, CA |
| 00000 000 | Frontier Medicines | Vice President of Business Development | 26-Feb-2024 | San Francisco, CA |
Fund Team Members (6)
| Name | Investor | Fund | Fund Location |
|---|---|---|---|
| Luc Verelst | Droia Ventures | Droia Ventures III | Zaventem, Belgium |
| Luc Verelst | Droia Ventures | Droia Ventures IV | Zaventem, Belgium |
| 000 0000000 | Droia Ventures | 00000 000000 | Zaventem, Belgium |
| 000000 00000 | Droia Ventures | 00000 000000 | Zaventem, Belgium |
| 000000 00000 | Droia Ventures | 00000 000000 | Zaventem, Belgium |
Janwillem Naesens Affiliated Funds (4)
| Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
|---|---|---|---|---|---|---|---|---|
| Droia Ventures I | Droia Ventures | Venture - General | Closed | 2014 | 000.0 | 000000 | 000000 | |
| Droia Ventures III | Droia Ventures | Venture - General | Closed | 2020 | 00000 | 000000 | 000000 | |
| Droia Ventures IV | Droia Ventures | Venture - General | Open | 2022 | 000000 | 000000 | ||
| Droia Ventures II | Droia Ventures | Venture - General | Closed | 2020 | 00000 | 000000 | 000000 |
Janwillem Naesens FAQs
-
Who is Janwillem Naesens?
Mr. Janwillem Naesens served as Chief Executive Officer and Board Member at Convert Pharmaceuticals.
-
How much does Janwillem Naesens typically invest?
Janwillem Naesens's median deal size is 000000.
-
What is Janwillem Naesens’s main position?
Janwillem Naesens’s primary position is Board Member.
-
How many active board seats does Janwillem Naesens hold?
Janwillem Naesens holds 4 board seats including Ambagon Therapeutics, Frontier Medicines, Highlight Therapeutics, and Octimet Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
